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Akt, better known as protein kinase B (PKB), is a serine/threonine-specific protein kinase which acts as mediator via
PI3K/Akt pathway in many biological processes like glucose metabolism, apoptosis, cell differentiation and
transcription. Akt1 gene amplification has been implicated in gastric carcinoma while Akt2 amplification has been
linked with ovarian, pancreas, breast and stomach tumors. The use of Akt inhibitors as monotherapy or in
combination with other anticancer drugs could be useful for combating drug resistance and improving response.
Thus, comprehensive understanding of Akt and its linked signaling pathways (PI3K, PKB, mTOR etc.) is necessary to
lead to newer drug development and use.Letter to the editor
Akt, better known as protein kinase B (PKB), is a serine/
threonine-specific protein kinase which acts as mediator
in many biological processes like glucose metabolism, apop-
tosis, cell differentiation and transcription. Three members
in the Akt family have been identified until now, namely
Akt1, Akt2 and Akt3. While Akt2 is mostly involved in glu-
cose transport and Akt3 is highly expressed in brain tissue,
Akt1 plays a key role cellular survival and metabolism [1,2].
The Akt cascade is activated by a host of events, most
commonly via binding of ligands such as growth factors,
cytokines and hormones to various receptors, the most
important of which are receptor tyrosine kinases (RTK)
(Figure 1). Binding of ligands to RTK causes autophospho-
rylation of tyrosine residues on the intracellular domain of
the receptor. This causes the recruitment of PI3K to the
phosphotyrosine residues via SH2 domain adapters in the
regulatory domain (p85) of PI3K. This causes conform-
ational changes in the catalytic domain of PI3K, which in
turn results in kinase activation. This is followed by the
PI3K mediated phosphorylation of membrane bound PIP2
to generate PIP3. PIP3 then binds to the PH domain of
Akt, thereby anchoring it to the plasma membrane and
allowing its phosphorylation and activation by PDK1 [3].* Correspondence: asfandyarsheikh@gmail.com
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and CTMP [4].
The mechanisms of involvement of the Akt pathway
in tumorigenesis are multifold. Activated Akt has well-
established anti-apoptotic activities. These are carried via
inhibition of release of cytochrome c from the mitochon-
dria or by its regulatory effect on various downstream effec-
tors, e.g. NF-κB, Bcl-2 family proteins, FOXO transcription
factors and MDM2, which in turn stimulate tissue growth
[5,6]. In addition, Akt activation mediates cell cycle pro-
gression via inhibition of glycogen synthase kinase 3beta,
opposing the action of p21WAF1 and p27Kip1 and by
phosphorylation of AKT/mTOR kinases [7]. The latter
results in increased translation of cyclin D1, D3, and E
transcripts and carries special significance with regard to
anti-cancer therapeutics. mTOR inhibition by rapamycin
derivative, everolimus, has been shown by Majumder et al.
to reverse AKT-dependent prostate intraepithelial neo-
plasia [8].
The Akt signaling pathway also influences other facets of
tumorigenesis. For example, Akt stimulates angiogenesis fa-
cilitating tumor growth [9]. This is due to the mediation of
the effects of VEGF by the Flk1/VEGFR2-PI3K-AKT path-
way [10]. Other hallmarks of malignancy such as tumor in-
vasion and metastasis are also affected by Akt activation
[11]. This is due to the increased secretion of matrix metal-
loproteinases and the induction of epithelial–mesenchymal
transition [12]. Akt has also been shown to stimulate tel-
omerase activity and replication [13].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The PI3K/Akt/mTOR signaling pathway [3].
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http://www.infectagentscancer.com/content/8/1/49The spectrum of mutations leading to Akt activation is
diverse and mostly affects the PI3K/Akt/mTOR pathway
(Table 1) [14]. Amplication and overexpression of Akt2
was first shown to occur in ovarian cancers [15]. Since
then, overexpression of Akt2 has been shown to occur
in pancreatic cancers, hepatocellular carcinomas, colo-
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Mutationsbreast cancers [16-19]. On the other hand, amplification
of Akt1 is relatively uncommon, and has been detected
in only a few cases of gastric carcinoma and gliosarcoma
[20,21]. Expression of Akt3 mRNA has also been found
to be upregulated in estrogen receptor-negative breast
carcinomas [22]. Furthermore, Akt has also been found
as a culprit for tumor cell resistance to chemotherapy14]
Cancer type
Breast, endometrial, colon, upper digestive tract, gastric, pancreas, ovarian,
liver, brain, oesophageal, lung, melanoma, urinary tract, prostate, thyroid
Lung (squamous cell), lung (adenocarcinoma), lung (small cell), lung
(non-small cell), cervical, breast, head and neck, gastric, thyroid,




Breast, colon, ovarian, lung, gastric
Ovarian, pancreas, head and neck, breast
Skin, glioblastoma
Glioblastoma, ovarian, colon
Gastric, breast, melanoma, prostate, glioblastoma
Endometrial, brain, skin, prostate, colon, ovary, breast, haematopoietic and
lymphoid tissue, stomach, liver, kidney, vulva, urinary tract, thyroid, lung
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http://www.infectagentscancer.com/content/8/1/49while treating breast cancer, ovarian cancer and pancre-
atic cancer [16,23]. A mutation in the Akt1 gene is also
known to cause the Proteus Syndrome [24]. Akt1, mea-
sured by immunohistochemistry techniques, has been
shown to be a marker of response to radiation therapy
in head and neck cancers [25].
A plethora of Akt inhibitors is under pre-clinical and
clinical trials. Various drug trials have been initiated for
Akt Inhibitors. However, miltefosine, is the only Akt in-
hibitor which has recently got approved by FDA albeit
for use in treatment of leishmaniasis. Akt inhibitors can
be divided into six major classes based on their mecha-
nisms of action. The first class contains ATP competitive
inhibitors of Akt. These include compounds such as
CCT128930 and GDC-0068, which inhibit Akt2 and
Akt1, respectively [26,27]. The latter has successfully en-
tered Phase II trials. This category also includes the pan-
Akt kinase inhibitors such as GSK2110183 (afuresertib),
which has entered Phase II trials, GSK690693, which en-
tered Phase I trials for refractory hematologic malignan-
cies, but was withdrawn prior to enrolment, and AT7867,
which is still in pre-clinical phase [28-30]. The second class
contains lipid-based Akt inhibitors which act by prevent-
ing the generation of PIP3 by PI3K. This mechanism is uti-
lized by phosphatidylinositol analogs such as Calbiochem
Akt Inhibitors I, II and III (category no. 124005, 124008,
124009 respectively) or other PI3K inhibitors such as PX-
866 [31]. This category also includes compounds such
as Perifosine that entered phase III trials for colorectal
cancer and multiple myeloma, but failed in 2012 [32].
The third class contains a group of compounds called
psuedosubstrate inhibitors. These include compounds
such as AKTide-2 T and FOXO3 hybrid [33,34]. The fourth
class consists of allosteric inhibitors of AKT kinase domain,
and include compounds such as MK2206. The fifth class
consists of antibodies and include entities such as GST-
anti-Akt1-MTS. The last class comprises of compounds
that interact with the PH domain of Akt, and include com-
pounds such as Triciribine and PX-316. Apart from these,
other molecules such as the Akt-1 Antisense Oligonucleo-
tide RX-0201, have also yielded favorable results [35].
In short, the use of Akt inhibitors as monotherapy or in
combination with other anticancer drugs could be useful
for combating drug resistance and improving response.
Thus, comprehensive understanding of Akt and its linked
signaling pathways (PI3K, PKB, mTOR etc.) is necessary
to lead to newer drug development and use [36].
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